Washington Just Flipped. This Health Care Giant Answered With a Raise.
November 5, 2026
The Cigna Group logo. Image from the company's newsroom media center, used for editorial identification.
- The Cigna Group (NYSE: CI) beat third-quarter estimates this morning, with adjusted earnings of $7.98 per share against roughly $7.52 expected, and raised its full-year outlook for the third time this year.
- The company sold its Medicare Advantage business last year and has little exposure to the Medicaid and Obamacare fights a new Democratic Congress is about to reopen.
- Near $312 premarket, the stock trades around 10 times this year's guided earnings, pays a $1.56 quarterly dividend, and management is targeting 10% to 14% annual earnings growth through 2030.
Wall Street got its answer on Wednesday. Democrats took both the House and the Senate, and the Dow jumped more than 1,500 points.
It was the index's best day since April 2025. Investors were not cheering a party. They were cheering gridlock, the idea that a split Washington makes sudden policy swings less likely.
But the rally was not even. Oil fell more than 8%. Chip stocks slid. And money poured into health care, which jumped about 3% as a sector.
The loudest gains went to insurers that live and die by Medicaid. Centene rose more than 12% on hopes the new Congress delays planned cuts.
One of the largest health companies in America moved far less. That was by design. And this morning, it reported a quarter that may matter more than any election.
The Company That Stepped Out of the Crossfire
Most investors still think of The Cigna Group (NYSE: CI) as the insurance card in their wallet. That is now the smaller part of the story.
Two years ago, Cigna agreed to sell its Medicare Advantage and Part D plans to Health Care Service Corporation. The deal closed in March 2025. It had already walked away from most government-run business before that.
What remains is built around employers. Large companies hire Cigna to run their health plans, and the bigger profit engine sits in a unit called Evernorth.
Think of Evernorth as two businesses under one roof. The first is Express Scripts, the pharmacy benefit manager. It works like a warehouse club for prescriptions, using the buying power of tens of millions of members to negotiate drug prices.
The second is the specialty pharmacy, and this is where the growth lives. Picture a retiree with rheumatoid arthritis on a biologic drug that costs thousands of dollars a month.
That medicine arrives at the door in a refrigerated box, with a nurse on call to walk through the first injection. Cigna's specialty arm serves more than one million patients with complex conditions like that.
It now produces about 37% of the company's earnings, and management wants it above 40% by 2030. New injectable drugs, from cancer therapies to weight-loss medicines, keep feeding it.
A Beat, a Raise, and Shares Being Retired
This morning's numbers were clean. Revenue rose 6% to $73.7 billion, ahead of the roughly $72.7 billion analysts expected.
Adjusted earnings came in at $7.98 per share, up from $7.83 a year ago and well above the consensus near $7.52.
The insurance side did the heavy lifting. Cigna Healthcare grew revenue 9% and pre-tax profit 15%, while its medical cost ratio held steady at 85%.
Management lifted its 2026 target to at least $30.60 per share. It raised the outlook in the first quarter, again in the second, and now again in the third.
Cash is going back to owners, too. The company repurchased about $500 million of stock, roughly 1.8 million shares, between the start of the quarter and this week.
The dividend was raised 6.8% this spring to $1.56 a quarter, and the next payment lands on December 17. At today's price that works out to a yield near 2%.
At its September investor day, Cigna laid out a plan for 10% to 14% annual earnings growth through 2030 and about $50 billion in operating cash flow over five years.
The One Number Worth Watching
Not everything moved the right way. Evernorth grew revenue 6%, but its pre-tax profit slipped 4% from a year ago.
Its margin dipped to 2.9% from 3.2%. Express Scripts is in the middle of rebuilding how it gets paid, moving away from the drug-maker rebates that critics have attacked for years.
The new rebate-free model rolls out to Cigna's own insured plans in 2027 and becomes the standard across Express Scripts in 2028. Transitions like that tend to cost money before they pay.
Pharmacy middlemen also remain a favorite target in Washington, from both parties. A Democratic Congress could put drug pricing back on the agenda, even if analysts do not expect quick changes.
Ten Times Earnings for a Double-Digit Grower
Here is what makes the setup unusual. Near $312 in premarket trading, the stock sits just below its 52-week high of about $316.
Yet it still trades around 10 times the $30.60 management now expects to earn this year. That is cheaper than many utilities, for a business guiding to double-digit earnings growth.
Wall Street is warming up. Fourteen analysts rate the shares a Buy and eight rate them a Hold.
The bear case has a number attached. Within the past year the stock traded near $240, roughly 23% below today's price, when medical costs and pharmacy reform fears were running hot.
If Evernorth's profit keeps sliding, or Washington moves faster on drug pricing than expected, that is the kind of drop investors could see again.
The Bottom Line
Wednesday's rally rewarded the health companies most tied to government programs. That is a political bet, and it can reverse with the next budget fight.
Cigna offers something different. Its customers are mostly employers, its growth comes from specialty drugs, and its earnings forecast keeps going up.
For a retirement portfolio, that combination is hard to find at 10 times earnings: a growing dividend, steady buybacks, and a company that stepped out of Washington's crossfire before the shooting started.
Disclaimer:
This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. Portions of this content may be drafted or assisted using artificial intelligence tools, with human review and editorial oversight prior to publication. All opinions expressed are based on publicly available data believed to be reliable but are not guaranteed for accuracy or completeness. Investing and trading involve risk, including the possible loss of principal. Always perform your own due diligence and consult with a qualified financial advisor before making investment decisions. Past performance is not indicative of future results. Paid ads from 3rd parties are clearly identified. We do NOT specifically endorse these products nor are we responsible for the content of these ads. You should assume an affiliate payment will be made to us if you click a link or buy a product. The publisher, its staff, contributors, and affiliates may hold positions in securities mentioned in this email and may buy or sell them at any time, including before or after publication. If a company whose securities we discuss has paid us directly for coverage, we will say so explicitly in that piece, including who paid and how much.